Denali and Biogen announce Phase 2b Parkinson's trial results for BIIB122

Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read

Key Changes

• high

  Denali and partner Biogen disclosed topline results from the Phase 2b LUMA study testing BIIB122 (DNL151) in early-stage Parkinson's disease patients. This represents a key clinical milestone for the company's neurodegenerative disease pipeline.

  Item 8.01 view on EDGAR →
• high

  The 8-K filing itself does not include efficacy data or trial outcomes—only that topline results were announced via press release on May 21, 2026. Investors should review the full press release for actual clinical data.

  Item 8.01 view on EDGAR →
• medium

  Press release dated May 21, 2026 attached as Exhibit 99.1 contains the detailed study results and company commentary on the LUMA trial outcomes.

  Exhibit 99.1 verify on EDGAR →